WO2004080396A3 - Curcumine liposomale pour traiter le cancer - Google Patents

Curcumine liposomale pour traiter le cancer Download PDF

Info

Publication number
WO2004080396A3
WO2004080396A3 PCT/US2004/006832 US2004006832W WO2004080396A3 WO 2004080396 A3 WO2004080396 A3 WO 2004080396A3 US 2004006832 W US2004006832 W US 2004006832W WO 2004080396 A3 WO2004080396 A3 WO 2004080396A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
curcumin
cancer
delivery system
treatment
Prior art date
Application number
PCT/US2004/006832
Other languages
English (en)
Other versions
WO2004080396A2 (fr
Inventor
Razelle Kurzrock
Lan Li
Kapil Mehta
Bharat Bhushan Aggarwai
Original Assignee
Univ Texas Md Anderson Cancer
Razelle Kurzrock
Lan Li
Kapil Mehta
Bharat Bhushan Aggarwai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas Md Anderson Cancer, Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwai filed Critical Univ Texas Md Anderson Cancer
Publication of WO2004080396A2 publication Critical patent/WO2004080396A2/fr
Publication of WO2004080396A3 publication Critical patent/WO2004080396A3/fr
Priority to US11/221,179 priority Critical patent/US7968115B2/en
Priority to US11/868,251 priority patent/US20080103213A1/en
Priority to US11/949,027 priority patent/US8784881B2/en
Priority to US13/117,807 priority patent/US9283185B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions et des procédés pour le traitement du cancer, notamment le cancer du pancréas, le cancer du sein et le mélanome chez un patient humain. Les procédés et compositions de l'invention comprennent de la curcumine ou un analogue de curcumine encapsulés dans un système d'administration de médicament colloïdal, de préférence un système d'administration de médicament liposomal. Ledit système d'administration de médicament colloïdal comprend également des nanoparticules, des nanocapsules, des microparticules ou des micelles à blocs copolymères. Le système d'administration de médicament colloïdal encapsulant la curcumine ou un de ses analogues est administré par voie parentérale dans un support pharmaceutiquement acceptable.
PCT/US2004/006832 2003-03-07 2004-03-05 Curcumine liposomale pour traiter le cancer WO2004080396A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/221,179 US7968115B2 (en) 2004-03-05 2005-09-07 Liposomal curcumin for treatment of cancer
US11/868,251 US20080103213A1 (en) 2004-03-05 2007-10-05 Liposomal curcumin for treatment of neurofibromatosis
US11/949,027 US8784881B2 (en) 2004-03-05 2007-12-01 Liposomal curcumin for treatment of diseases
US13/117,807 US9283185B2 (en) 2003-03-07 2011-05-27 Liposomal curcumin for treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45263003P 2003-03-07 2003-03-07
US60/452,630 2003-03-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11221179 A-371-Of-International 2004-03-05
US13/117,807 Continuation US9283185B2 (en) 2003-03-07 2011-05-27 Liposomal curcumin for treatment of cancer

Publications (2)

Publication Number Publication Date
WO2004080396A2 WO2004080396A2 (fr) 2004-09-23
WO2004080396A3 true WO2004080396A3 (fr) 2004-12-02

Family

ID=32990665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006832 WO2004080396A2 (fr) 2003-03-07 2004-03-05 Curcumine liposomale pour traiter le cancer

Country Status (1)

Country Link
WO (1) WO2004080396A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12004868B2 (en) * 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US8784881B2 (en) 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
EP1993365B1 (fr) * 2006-03-06 2013-05-08 The Regents of the University of California Formulations de curcuminoïde biodisponibles pour traiter la maladie d'alzheimer et d'autres troubles associés à l'âge
EP2076129B1 (fr) 2006-10-12 2016-05-04 Research Foundation Of The City University Of New York Nouveaux curcumine dimère
WO2008085984A1 (fr) * 2007-01-08 2008-07-17 Androscience Corporation Composés comprenant un groupe caractéristique de propénal (substitué par du phényle), leurs dérivés, leur activité biologique et leurs utilisations
CN101569607B (zh) * 2009-06-16 2011-02-16 中国药科大学 一种双脱甲氧基姜黄素的前体脂质体及其制备方法
WO2011101859A1 (fr) * 2010-02-22 2011-08-25 Institute Of Life Sciences Nouveau système nanoparticulé chargé de curcumine soluble dans l'eau pour thérapie cancéreuse
US9393198B2 (en) * 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
WO2012024405A2 (fr) * 2010-08-17 2012-02-23 The Ohio State University Compositions de curcumine et utilisations de celles-ci
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
WO2012167212A2 (fr) 2011-06-03 2012-12-06 Signpath Pharma Inc. Atténuation liposomale du syndrome du qt long induit par un médicament et du courant de potassium à redressement retardé
DE112013004278T5 (de) 2012-08-31 2015-05-21 Signpath Pharma Inc. Curcumin-Er, ein liposomales PLGA-Nanocurcumin mit verlängerter oder verzögerter Freisetzung zur Minimierung der QT-Verlängerung für eine Krebstherapie
WO2014192024A1 (fr) * 2013-05-20 2014-12-04 Sree Chitra Tirunal Institute For Medical Sciences And Technology Développement de curcumine albuminée soluble pour application en thérapie anticancéreuse
EP3082768B1 (fr) 2013-12-18 2023-02-22 Signpath Pharma Inc. Atténuation liposomale de l'inhibition induite par médicament du canal ikr cardiaque
EP3225112B1 (fr) 2016-04-01 2021-08-18 TriOptoTec GmbH Dispersion de photosensibilisant et son utilisation
CA3038813C (fr) 2016-04-27 2021-08-24 Signpath Pharma, Inc. Prevention d'un bloc atrio-ventriculaire induit par des medicaments
AU2017286151B2 (en) * 2016-06-13 2019-05-16 China Medical University Novel derivatives of curcuminoids and use thereof as an anticancer agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
DE10029770A1 (de) * 2000-06-16 2001-12-20 Transmit Technologietransfer Verwendung von Curcuminen zur Behandlung von soliden Tumoren,insbesondere von Hirntumoren
WO2002002582A1 (fr) * 2000-06-30 2002-01-10 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Derives de curcumine a solubilite dans l'eau amelioree vis-a-vis de la curcumine, et medicaments renfermant ces derives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
DE10029770A1 (de) * 2000-06-16 2001-12-20 Transmit Technologietransfer Verwendung von Curcuminen zur Behandlung von soliden Tumoren,insbesondere von Hirntumoren
WO2002002582A1 (fr) * 2000-06-30 2002-01-10 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Derives de curcumine a solubilite dans l'eau amelioree vis-a-vis de la curcumine, et medicaments renfermant ces derives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUANG M.-T. ET AL: "Inhibitory effects of curcumin on tumor initiation by benzo(a)pyrene and 7,12-dimethylbenz(a)anthracene", CARCINOGENESIS, vol. 13, no. 11, 1992, pages 2183 - 2186, XP008044662 *
KUTTAN R. ET AL: "Potential anticancer activity of turmeric (curcuma longa)", CANCER LETTERS, vol. 29, 1985, pages 197 - 202, XP001120343 *
RANADE V.V.: "Drug delivery systems. 1. site-specific drug delivery using liposomes as carriers", J. CLIN. PHARMACOL., vol. 29, 1989, pages 685 - 694, XP002982134 *
SAMABA H.S. ET AL: "Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention and promotion", CANCER RESEARCH, vol. 57, April 1997 (1997-04-01), pages 1301 - 1305, XP002982133 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12004868B2 (en) * 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel

Also Published As

Publication number Publication date
WO2004080396A2 (fr) 2004-09-23

Similar Documents

Publication Publication Date Title
WO2004080396A3 (fr) Curcumine liposomale pour traiter le cancer
MXPA05010565A (es) Sistemas de suminsitro de farmacos que comprenden un ingrediente activo encapsulado.
EA200600877A1 (ru) Наночастицы для доставки лекарств
WO2003082247A3 (fr) Microparticules medicamenteuses
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
WO2002070438A3 (fr) Compositions permettant l'administration de biophosphonates
EP2322217A3 (fr) Traitement combiné pour malignités non hematologiques par anticorps anti-IGF-1R
MY141584A (en) Pharmaceutical uses of bisphosphonates
WO2005079867A3 (fr) Particules d'hydroxyapatite emettrices de rayons alpha
PL372925A1 (en) Prevention and treatment of restenosis by local administration of drug
WO2004069169A3 (fr) Distribution localisee d'un medicament au moyen de nanocapsules chargees de medicament
MXPA05007266A (es) Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
HUP0203590A2 (hu) Gyógyszerkészítmény a csonttömeg csökkenésével járó betegségek kezelésére
DK1392254T3 (da) Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
WO2002089778A3 (fr) Systeme therapeutique transdermique destine au traitement de la maladie de parkinson induisant des niveaux de plasma eleves de rotigotine
MY128362A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
HK1068606A1 (en) Novel aminobenzoephenones
TW200509998A (en) Controlled release of highly soluble agents
EP1262197A3 (fr) Combinaison thérapeutique pour traiter les troubles du sommeil, y compris l'apnée du sommeil
CA2585754C (fr) Formulations de medicaments insolubles dans l'eau ou faiblement solubles dans l'eau dans des particules de glycosaminoglycane lipides et leur utilisation dans des diagnostics et une therapie
WO2002078690A3 (fr) Agents anti-tumoraux taxoides et compositions pharmaceutiques basees sur ces derniers
WO2003039437A3 (fr) Preparation pharmaceutique d'administration orale contenant du paclitaxel encapsule dans des liposomes
EP1273301A3 (fr) Préparations pharmaceutiques comprenant des principes actifs susceptibles d'administration illicite
WO2004014306A3 (fr) Compositions et procedes de traitement de maladies presentant un defaut d'assemblage et une agregation de proteines
WO2004073627A3 (fr) Methode et compositions therapeutiques pour administration topique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11221179

Country of ref document: US

122 Ep: pct application non-entry in european phase